Back Avineuro Pharmaceuticals, Inc.
A Global Neuroscience Research And Development Company Developing novel small molecules to treat unmet medical needs in the neurological and psychiatric fields.
Avineuro Pharmaceuticals, Inc. announces beginning of Phase I clinical studies of AVN-211, potent small molecule for treatment of schizophrenia.
San Diego, CA – March 5th, 2009 – Avineuro Pharmaceuticals, Inc. announced today an initiation of Phase I clinical studies of AVN-211, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of Schizophrenia. The results of Phase I studies are expected to be available in April 2009. Based on these and other results, Avineuro Pharmaceuticals, Inc. plans to advance AVN-211 into Phase II clinical trials in Q2 2009. Avineuro Pharmaceuticals, Inc. will present at the 9th International Conference – AD/PD 2009 – Prague, Czech Republic, March 11-15, 2009.
About Avineuro Pharmaceuticals, Inc.:
Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.
Contact:
Yan Lavrovsky, CEO
Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive, Suite 126
San Diego, CA 92121
Tel 858-436-1537 / 858-436-1540
Fax 858-228-9798
Email: YLavrovsky@avineuro.com